Key Points
- Major shareholder Squadron Capital sold 302,369 OrthoPediatrics shares at an average price of $21.01, generating approximately $6.35 million. The sale reduced its ownership by 4.65%, though it retained about 6.2 million shares.
- OrthoPediatrics reported quarterly revenue of $70.51 million and an adjusted earnings loss of $0.26 per share, exceeding analysts’ expectations for both revenue and EPS.
- Analyst sentiment remains positive, with a consensus “Moderate Buy” rating from 11 analysts and an average price target of $26.44; institutional investors own approximately 69% of the company.
OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) major shareholder Squadron Capital Llc sold 302,369 shares of the firm's stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the transaction, the insider directly owned 6,201,764 shares of the company's stock, valued at $130,299,061.64. The trade was a 4.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Squadron Capital Llc also recently made the following trade(s):
- On Wednesday, September 2nd, Squadron Capital Llc sold 22,500 shares of OrthoPediatrics stock. The shares were sold at an average price of $23.35, for a total value of $525,375.00.
- On Friday, August 28th, Squadron Capital Llc sold 326,700 shares of OrthoPediatrics stock. The shares were sold at an average price of $23.04, for a total transaction of $7,527,168.00.
- On Tuesday, September 1st, Squadron Capital Llc sold 10,131 shares of OrthoPediatrics stock. The shares were sold at an average price of $23.10, for a total transaction of $234,026.10.
- On Wednesday, August 26th, Squadron Capital Llc sold 18,000 shares of OrthoPediatrics stock. The stock was sold at an average price of $24.28, for a total value of $437,040.00.
- On Tuesday, August 25th, Squadron Capital Llc sold 16,300 shares of OrthoPediatrics stock. The stock was sold at an average price of $24.74, for a total value of $403,262.00.
- On Monday, August 24th, Squadron Capital Llc sold 4,000 shares of OrthoPediatrics stock. The stock was sold at an average price of $25.75, for a total transaction of $103,000.00.
OrthoPediatrics Stock Up 2.3%
KIDS opened at $22.06 on Friday. The business's fifty day simple moving average is $22.01 and its 200 day simple moving average is $19.04. OrthoPediatrics Corp. has a 52 week low of $14.42 and a 52 week high of $26.74. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The stock has a market cap of $575.99 million, a PE ratio of -13.13 and a beta of 0.99.
OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The company had revenue of $70.51 million for the quarter, compared to analysts' expectations of $68.21 million. As a group, research analysts expect that OrthoPediatrics Corp. will post -1.14 earnings per share for the current fiscal year.
Hedge Funds Weigh In On OrthoPediatrics
Several institutional investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in shares of OrthoPediatrics in the 2nd quarter worth $24,347,000. Millennium Management LLC lifted its position in OrthoPediatrics by 48.0% during the fourth quarter. Millennium Management LLC now owns 1,396,495 shares of the company's stock valued at $24,802,000 after purchasing an additional 452,840 shares in the last quarter. AIGH Capital Management LLC purchased a new position in OrthoPediatrics during the second quarter valued at $5,161,000. Nantahala Capital Management LLC bought a new stake in OrthoPediatrics during the second quarter valued at about $4,636,002. Finally, AWM Investment Company Inc. bought a new stake in OrthoPediatrics during the second quarter valued at about $4,537,000. Institutional investors own 69.05% of the company's stock.
Trending Headlines about OrthoPediatrics
Here are the key news stories impacting OrthoPediatrics this week:
- Positive Sentiment: OrthoPediatrics crossed the $70 million revenue level and reportedly increased its guidance, signaling continued demand for its pediatric orthopedic products and potentially stronger future growth. OrthoPediatrics Crosses $70M as Guidance Climbs Higher
- Positive Sentiment: Analyst sentiment remains favorable: nine analysts rate the stock Buy, one rates it Hold and one rates it Sell. The consensus rating is Moderate Buy with an average price target of $26.44; BTIG and Needham recently raised their targets to $29 and $35, respectively.
- Positive Sentiment: Institutional ownership is substantial at approximately 69%, while several investment firms—including Millennium Management, BlackRock, Granahan Investment Management and Wasatch Advisors—have recently increased or initiated positions.
- Neutral Sentiment: Reported short interest was zero shares as of September 10, leaving no meaningful short-covering catalyst or bearish short-position overhang.
- Negative Sentiment: Director David Pelizzon, also identified in related filings as major shareholder entities associated with Jennifer Pritzker and Squadron Capital, sold 302,369 shares at an average price of $21.01 for approximately $6.35 million. The sale reduced the reported holding by 4.65%, which may pressure sentiment, although the insider still retained about 6.2 million shares. SEC Insider Sale Filing
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on the stock. BTIG Research raised their target price on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Thursday, August 20th. Needham & Company LLC upped their target price on OrthoPediatrics from $30.00 to $35.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. TD Cowen reaffirmed a "buy" rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Truist Financial set a $22.00 price objective on OrthoPediatrics in a research report on Wednesday, August 5th. Finally, Piper Sandler restated an "overweight" rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, OrthoPediatrics currently has a consensus rating of "Moderate Buy" and a consensus price target of $26.44.
Get Our Latest Stock Report on OrthoPediatrics
OrthoPediatrics Company Profile
(
Get Free Report)
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
